CD34 stem cell-related methods and compositions

Details CD34 stem cell-related methods and compositions CD34 stem cell-related methods and compositions

2011-08-16

2011-08-16

Schultz, Doug (Department: 1633)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C514S04400A, C435S006120, C435S325000

Reexamination Certificate

active

07998472

ABSTRACT:
This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34−stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34−stem cells used in the instant methods can be genetically modified or not, depending on the disorder treated.

REFERENCES:
patent: 6361997 (2002-03-01), Huss
patent: 2002/0127715 (2002-09-01), Benvenisty et al.
patent: 2003/0082155 (2003-05-01), Habener et al.
patent: 2004/0220384 (2004-11-01), Hinuma et al.
patent: 2008/0241115 (2008-10-01), Suh et al.
patent: WO99/37332 (1999-07-01), None
patent: WO03/010305 (2003-02-01), None
patent: WO 03/025167 (2003-03-01), None
patent: WO2004/007697 (2004-01-01), None
patent: WO2005/026335 (2005-03-01), None
patent: WO2005/093044 (2005-10-01), None
Khalil, et al., Nonmyeloablative Stem Cell Therapy Enhances Microcirculation and Tissue Regeneration in Murine Inflammatory Bowel Disease,Gastroenterology, Mar. 2007 132:944-954.
Torrente, et al., Identification of a putative pathway for the muscle homing of stem cells in a muscular dystrophy model, J. Cell. Bio., vol. 162, No. 3 pp. 511-520 (2003).
Conrad et al., Adult Stem Cell Lines I Regenerative Medicine and Reconstructive Surgery,J. Surg. Res., vol. 124 No. 2, pp. 201-208 (2005).
Anderson et al., The Mouse Dystrophin Muscle Promoter/Enhancer Drives Expression of Mini-dystrophin in TransgenicmdxMice and Rescues the Dystrophy in These Mice,Mol. Ther., Nov. 2006 vol. 14, No. 5 pp. 724-734.
Cooper et al., In vivo satellite cell activation via Myf5 and MyoD in regeneration mouse skeletal muscle,J. Cell. Sci., 1999, vol. 112, No. 17 pp. 2895-2901.
Fessele S, Maier H, Zischek C, Nelson PJ, Werner T. Regulatory context is a crucial part of gene function. Trends Genet. Feb. 2002;18(2):60-3. PubMed PMID: 11818130.
Rols, et al. “Electopermeabilization of mammalian cells” Biophys J. Biophysical Society; vol. 58;pp. 1089-1098; Nov. 1990.
Schlaeger et al. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice: The National Academy of Sciences of the USA; vol. 94; pp. 3058-3063, Apr. 1997.
Torchilin “Recent Approaches to Intracellular Delivery of Drugs and DNA and Organelle Targeting” Annu. Rev. Biomed. Eng. 2006. 8:343-75.
Lüttichau, et al. “Human Adult CD34—Progenitor Cells Functionally Express the Chemokine Receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but Not CXCR4” Stem Cells and Development 14:329-336 (2005).
Wennersten, et al. “Proliferation, migration, and differentiation of human neural stem/progenitor cells after transplantation into a rat model of traumatic brain injury” J Neurosurg 100:88-96, 2004.
Wu, et al. “Production of viral vectors for gene therapy applications” Department of Chemical Engineering and Center for Biotechnology and Bioengineering, 2000, 11:205-208.
Kanerva, et al. “Adenoviruses for treatment of cancer” Annals of Medicine, 2005; 37: 33-43.
Kojaoghlanian, et al. “The impact of adenovirus infection on the immunocompromised host” Rev. Med. Virol. 2003; 13: 155-171.
Lakso, et al. “Targeted oncogene activation by site-specific recombination in transgenic mice” Proc. Nail. Acad. Sci. USA vol. 89, pp. 6232-6236, Jul. 1992.
Orban, et al. “Tissue- and site-specific DNA recombination in transgenic mice” Proc. Natl. Acad. Sci. USA vol. 89, pp. 6861-6865, Aug. 1992.
Aiuti et al., Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyelablative Conditioning,Science, New Series, vol. 296, No. 5577 (Jun. 28, 2002), pp. 2410-2413, American Association for the Advancement of Science.
Armentano, et al., Characterization of an Adenovirus Gene Transfer Vector Containing an AE4 Deletion, Human Gene Therapy 6:1343-1353 (Oct. 1995).
Atchison, et al., Adenovirus-Associated Defective Virus Particles,Science, New Series, vol. 149, No. 3685 (Aug. 13, 1965), pp. 754-756, American Association for the Advancement of Science.
Becerra, et al., Synthesis of Adeno-Associated Virus Structural Proteins Requires Both Alternative mRNA Splicing and Alternative Initiations from a Single Transcript, Journal of Virology, Aug. 1988, p. 2745-2754.
Gerd Bendas, Immunoliposomes a Promising Approach to Targeting Cancer Therapy, BioDrugs 2001; 15(4); 215-224.
Benihoud et al., Adenovirus vectors for gene delivery, Current Opinion in Biotechnology 1999, 10:440-447.
Bett et al., An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3,Proc. Natl Acad. Sci. USA, vol. 91, pp. 8802-8806 Sep. 1994.
Beyer, et al., Oncoretrovirus and Lentivirus Vectors Pseudotyped with Lymphocytic Chriomeningitis Virus Glycoprotein: Generation, Concentration, and Broad Host Range, Journal of Virology, Feb. 2002, p. 1488-1495.
Bradfute et al., Adenoviral Transduction of Mouse Hemotapoietic Stem Cells, Molecular Therapy vol. 7, No. 3, Mar. 2003.
Yazawa, et al. “Current Progress in Suicide Gene Therapy for Cancer” World J. Surg. 26, 783-789, 2002 DOI: 10.1007/s00268-002-4053-5.
Young, et al. “Viral gene therapy strategies: from basic science to clinical application” Journal of Pathology J Pathol 2006; 208: 299-318.
Flierl, et al. “Adeno-associated virus-mediated gene transfer of the heart/muscle adenine nucleotide translocator (ANT) in mouse” Gene Therapy (2005) 12, 570-578.
Gabriel, et al. “Direct Observation in the Millisecond Time Range of Fluorescent Molecule Asymmetrical Interaction with the Electropermeabilized Cell Membrane” Biophysical Journal vol. 73 Nov. 1997 2630-2637.
Gaspar, et al. “Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector” www.thelancet.com vol. 364 Dec. 18-25, 2004.
Grill, et al. “Robust Growth of Chronically Injured Spinal Cord Axons Induced by Grafts of Genetically Modified NGF-Secreting Cells” Experimental Neurology 148, 444-452 (1997).
Hagan, et al. “Neuroprotection by human neural progenitor cells after experimental contusion in rats” M. Hagan et al. / Neuroscience Letters 351 (2003) 149-152.
Hämmerling, et al. “Vascular Integration of Endothelial Progenitors During MultistepTumor Progression” [Cell Cycle 5:5, 509-511, Mar. 1, 2006]; © 2006 Landes Bioscience.
IzsvaÂk, et al. “Sleeping Beauty, a Wide Host-range Transposon Vector for Genetic Transformation in Vertebrates” http://www.idealibrary.com on J. Mol. Biol. (2000) 302, 93-102 0022-2836.
Cavazzana-Calvo, et al., Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease,Science, New Series, vol. 288, No. 5466 (Apr. 28, 2000), pp. 669-672, American Association for the Advancement of Science.
Cochrane, et al., Specific interaction of the human immunodeficiency virus Rev protein with a structured region in the env mRNA,Pro. Natl. Acad. Sci. USA, vol. 87, pp. 1198-1202, Feb. 1990.
Dancer, et al., Expression of thymidine kinase driven by an endothelial-specific promoter inhibits tumor growth of Lewis lung carcinoma cells in transgenic mice, Gene Therapy (2003) 10, 1170-1178.
Danthinne, et al., Production of first generation adenovirus vectors: a review, Gene Therapy (2000) 7, 1707-1714.
Danthinne, et al., New Tools for the generation of E1- and/or E3-substituted adenoviral vectors, Gene Therapy (2000) 7, 80-87.
Derossi, et al., Cell Internalization of the Third Helix of the Antennapedia Homeodomain Is Receptor-independent, The Journal of Biological Chemistry, vol. 271, No. 30, Issue of Jul. 26, pp. 18188-18193, 1996.
Dupré, et al., Efficacy of Gene Therapy for Wiskott-Aldrich Syndrome Using aWASPromoter/cDNA-Containing Lentiviral Vector and Nonlethal Irradiation, Human Gene Therapy 17:303-313 (Mar. 2006).
Susan M. Dymecki, Flip recombinase promotes site-specific DNA recombination in embryonic stem cells and transgenic mice,Pro. Natl. Acad. Sci

Affiliated with

Also associated with

Rating

CD34 stem cell-related methods and compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with CD34 stem cell-related methods and compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD34 stem cell-related methods and compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2630509